香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 關於召開臨時股東大會的提示性公告 本公司根據於 2025 年 12 月 9 日舉行的臨時股東大會會議（「臨時股東大會」）召開前 十（10）日收到的書面回覆計算，擬出席臨時股東大會的股東所代表的有表決權的股份 數尚未達到本公司有表決權的股份總數的二分之一（1/2）以上。根據本公司的章程第 七十七條規定，本公司現將召開臨時股東大會的相關事宜作提示性公告如下： 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 11 月 28 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生； 非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生 及萬鈞女士。 * ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain [1]

证券代码：601607 证券简称：上海医药 编号：临 2025-109 上海医药集团股份有限公司 关于盐酸曲马多注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海禾丰制药 有限公司（以下简称"上药禾丰"）的盐酸曲马多注射液（以下简称"该药品"） 收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品补充申请批 准通知书》（通知书编号：2025B05705），该药品通过仿制药质量和疗效一致 性评价。 一、该药品基本情况 上海医药集团股份有限公司 二、该药品相关的信息 盐酸曲马多注射液主要用于治疗中度至重度疼痛。由 Grünenthal GmbH 公司 研发，最早于 1977 年在德国上市。2024 年 8 月，上药禾丰就该药品仿制药质量 和疗效一致性评价向国家药品监督管理局提出补充申请并获得受理。截至本公告 日，公司针对该药品的一致性评价已投入研发费用约为人民币 152 万元。 截至本公告日，中国境内该药品的主要生产厂家有瑞阳制 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-108 上海医药集团股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海医药集团股份有限公司（以下简称"上海医药"、"公司"）于2025 年11月19日在《中国证券报》、《上海证券报》、《证券日报》、《证券时报》 和上海证券交易所网站（www.sse.com.cn）上刊登了《上海医药集团股份有限 公司关于召开2025年第二次临时股东大会的通知》（临2025-107），定于2025 年12月9日以现场投票和网络投票相结合的方式召开2025年第二次临时股东大 会。现将本次会议的有关事项提示如下 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 1 股东大会召开日期：2025年12月9日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), received a Supplementary Application Approval Notice from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain [1]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - The approved drug is primarily used for the treatment of moderate to severe pain [1]

Group 1 - The A-share market has seen 69 stocks being continuously bought on margin for over 5 days, with 6 stocks experiencing this for 9 consecutive days, indicating a strong interest from investors [1] - The current market environment is likened to a precise gambling game, where traditional strategies like "leading stocks driving others" are failing due to rapid shifts in market hotspots [3] - The phenomenon of stocks being bought on margin reflects a structural layout by major funds rather than short-term speculation, with stocks spread across various sectors such as pharmaceuticals, military, and electricity [9] Group 2 - Successful stocks share two common characteristics: a phenomenon of aggressive buying and the art of shaking off weak hands before a price increase [4][6] - Data from trading systems reveal that stock price movements are not random, as evidenced by stocks that have been continuously bought on margin [9] - The speed of industry rotation is increasing, making human analysis insufficient, while true opportunities are often hidden in data details [10]

Core Insights - As of November 25, a total of 69 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stocks with the longest streak of net financing inflows, at nine consecutive trading days, include Shanghai Pharmaceuticals, Lutai A, Guokai Military Industry, Gongda High-Tech, Shuangle Co., and Huadian International [1] - Other notable stocks with significant net financing inflows include Qibin Group, Zhuoyue Technology, Changyuan Electric Power, Dongcai Technology, Bailong Oriental, Zhongchen Technology, Hongchuan Wisdom, and Tongbao Energy [1]